Oncologists Offer Recommendations for Lowering Cost of Cancer Drugs

Share this content:
Soaring costs for cancer drugs are detrimental to patient care in the United States, say a group of oncologists.
Soaring costs for cancer drugs are detrimental to patient care in the United States, say a group of oncologists.

Soaring costs for cancer drugs are detrimental to patient care in the United States, say a group of oncologists.

Recommendations on how to address the problem are presented in a commentary piece published in the Mayo Clinic Proceedings.

Allowing Medicare to negotiate drug prices is one of the suggestions the team of 118 leading cancer experts offered as a possible solution.

Along with their recommendations, the group also expressed support for a patient-based grassroots movement on change.org that is demanding action on the issue.

The changes the commentary called for also included:

  1. create a review mechanism after a drug has been approved by the U.S. Food and Drug Administration that would propose a fair price for new cancer drugs that is based on the value to patients and health care
  2. allow the Patient-Centered Outcomes Research Institute -- established under the Affordable Care Act -- to evaluate the benefits of new cancer therapies, and let similar organizations include drug prices in their assessments of a treatment's value
  3. permit patients to import cancer drugs from other countries (e.g., prices in Canada are about half that of prices in the United States)
  4. pass legislation to prevent drug companies from delaying the introduction of generic drugs, and reform the patent system to make it more difficult to unnecessarily extend patent protection of a drug
  5. encourage groups that represent cancer specialists and patients to consider the overall value of drugs and treatments when developing their treatment guidelines

"It should be possible to focus the attention of pharmaceutical companies on this problem and to encourage our elected representatives to more effectively advocate for the interests of their most important constituents among the stakeholders in cancer -- American cancer patients," the authors write.

RELATED: Cost Burdens on Patients Older than 66 with Oral Cavity, Pharyngeal Cancers

The authors disclosed financial ties to the pharmaceutical and biotechnology industries.

Reference

  1. Tefferi A, Hagop K, Rajkumar SV, et al. In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. Mayo Clinic Proceedings. DOI: http://dx.doi.org/10.1016/j.mayocp.2015.06.001. [epub ahead of print]. July 23, 2015.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters